Thu, December 19, 2024
[ Thu, Dec 19th 2024 ]: The Motley Fool UK
2 FTSE 100 stocks that could outperform the index in 2025
[ Thu, Dec 19th 2024 ]: Bloomberg L.P.
What's Next for Five of 2024's Most Dramatic Tech Stock Stories
[ Thu, Dec 19th 2024 ]: Seeking Alpha
Where Do Stocks Go From Here?
[ Thu, Dec 19th 2024 ]: moneycontrol.com
Super Fund Manager 2024: How this fund manager is winning the infra game with 47% return in a year
[ Thu, Dec 19th 2024 ]: Morningstar
The 60/40 Portfolio in 2025: What to Expect
[ Thu, Dec 19th 2024 ]: Analytics Insight
Invest Wisely: Your Step-by-Step Guide on How to Invest in Stocks
[ Thu, Dec 19th 2024 ]: Business Insider
Stocks tanked after the Fed signaled fewer rate cuts next year. Here's what analysts are saying.
[ Thu, Dec 19th 2024 ]: bnnbloomberg
S&P 500 Buyers Step in Ahead of Fed Meet Despite Narrow Breadth
[ Thu, Dec 19th 2024 ]: Daily Express
Russia faces construction nightmare as stocks in country's biggest company plummet
[ Thu, Dec 19th 2024 ]: The Motley Fool
Could This 1 Thing That's Happened Only 3 Times i .. &P 500's Gains in 2025? Here's What History Says.
[ Thu, Dec 19th 2024 ]: The Motley Fool
3 Top Stocks That Could Double in 2025
[ Thu, Dec 19th 2024 ]: The Daily Telegraph
'American tech stocks aren't working for me - how can I make big returns in five years?'
[ Thu, Dec 19th 2024 ]: Investing
S&P 500: Why Investing in the Benchmark Index Should Be Your Next Move
[ Thu, Dec 19th 2024 ]: The Globe and Mail
2 Stocks Set to Dominate in 2025
[ Thu, Dec 19th 2024 ]: Indiatimes
Sensex Today | Stock Market LIVE Updates: Sensex .. rs bleed; Transrail Lighting IPO fully subscribed
[ Thu, Dec 19th 2024 ]: MarketWatch
Stock Market Today: Dow ends down over 1,100 poin .. lowers interest rates, signals fewer cuts in 2025
[ Thu, Dec 19th 2024 ]: MSN
A 10% dividend yield? There could be significant potential here to earn a second income
[ Thu, Dec 19th 2024 ]: Reuters
US stocks face headwind from rising yields after Fed signals fewer rate cuts
[ Thu, Dec 19th 2024 ]: Indiatimes
Inventurus Knowledge Solutions Share Price Live: IKS shares list at 43% premium over IPO price
[ Thu, Dec 19th 2024 ]: MSN
Gianni Kovacevic: 3 Copper Stocks for Speculators, Watch These Metals Under Trump
[ Thu, Dec 19th 2024 ]: Yahoo
SoftwareOne announces deal to buy Norwegian rival Crayon
[ Thu, Dec 19th 2024 ]: Seeking Alpha
How To Defend Against More 3% S&P 500 Down Days Like Wednesday
[ Thu, Dec 19th 2024 ]: The Financial Express
Chennai Petro, ONGC, HPCL, Vedanta in list of top .. cks: Check list of key dividend paying stocks now
Wed, December 18, 2024
[ Wed, Dec 18th 2024 ]: CNN-News18
Stocks To Watch: SBI, Infosys, IndusInd Bank, NITCO, VIP Industries And Others
[ Wed, Dec 18th 2024 ]: moneycontrol.com
Firms close to IPOs are seeing good interest from rich Indians: Sandipan Roy
[ Wed, Dec 18th 2024 ]: Money Morning
Quantum Computing Primer: How It Works and the Top Stocks to Watch
[ Wed, Dec 18th 2024 ]: CNN
Fed set to cut rates for third and final time this year
[ Wed, Dec 18th 2024 ]: The New York Times
Stocks Plunge as Fed Forecasts Fewer Rate Cuts Next Year
[ Wed, Dec 18th 2024 ]: MarketWatch
Stock Market Today: Dow trims gain after Fed cuts rates, signals fewer cut going forward
[ Wed, Dec 18th 2024 ]: The Motley Fool UK
Up 107% in 2024, can this FTSE 250 star keep soaring?
[ Wed, Dec 18th 2024 ]: Motley Fool Australia
Buy and hold Telstra and these ASX dividend shares in 2025
[ Wed, Dec 18th 2024 ]: bnnbloomberg
European Stocks Cap Four Days of Losses as Focus Shifts to Fed
[ Wed, Dec 18th 2024 ]: Investopedia
6 Stocks To Consider Buying Before Year-End
[ Wed, Dec 18th 2024 ]: Financial Post
Is a $100 million TFSA possible?
[ Wed, Dec 18th 2024 ]: 24/7 Wall St
3 Top Schwab ETFs to Buy in 2025
[ Wed, Dec 18th 2024 ]: Kiplinger
Why Birkenstock Is Still a Buy After Earnings
[ Wed, Dec 18th 2024 ]: The Daily Mirror
Two-thirds of young investors take less than 24 hours to decide on an investment
[ Wed, Dec 18th 2024 ]: The Motley Fool
Here's My Top Dividend Stock for 2025
[ Wed, Dec 18th 2024 ]: The Globe and Mail
2 Spectacular Artificial Intelligence (AI) Stocks Primed to Beat the S&P 500 in 2025
[ Wed, Dec 18th 2024 ]: Business Insider
History says getting out of stocks now could be a major mistake
[ Wed, Dec 18th 2024 ]: Forbes
Best High-Return Stocks In India
[ Wed, Dec 18th 2024 ]: Seeking Alpha
Alger International Opportunities Fund Q3 2024 Commentary
[ Wed, Dec 18th 2024 ]: MSN
Best balanced advantage funds or dynamic asset allocation funds to invest in December 2024
Tue, December 17, 2024
[ Tue, Dec 17th 2024 ]: The Motley Fool
Why Shares in Aehr Test Systems Shot Higher by 25% Today (Hint: It's AI Related)
[ Tue, Dec 17th 2024 ]: Reuters
Investor allocations to US equities at record high, to cash at record low, BofA says
[ Tue, Dec 17th 2024 ]: MSN
Emerging Canadian Tech Leaders to Invest in for Long-Term Gains
[ Tue, Dec 17th 2024 ]: Yahoo Finance
Bank of America Corporation (BAC): One of The Bes .. y Now According to Billionaire Hedge Fund Manager
[ Tue, Dec 17th 2024 ]: Seeking Alpha
SPYD: Susceptible To Holding Dividend Yield Traps

Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -this-company-has-the-best-weight-loss-drug.html
  Print publication without navigation Published in Stocks and Investing on by The Motley Fool
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose weight. A recent study found that it may not be Ozempic or Wegovy that's the best weight loss drug. Instead, that could come from Novo Nordisk's longtime rival, Eli Lilly ( LLY -0.17%).
The article from The Motley Fool discusses a head-to-head study comparing Ozempic, a popular weight loss drug, with Mounjaro, another weight loss medication. The study, which was published in the Journal of the American Medical Association (JAMA), found that Mounjaro (tirzepatide) outperformed Ozempic (semaglutide) in terms of weight loss efficacy. Participants on Mounjaro lost significantly more weight than those on Ozempic, with the study highlighting Mounjaro's dual mechanism of action targeting both GLP-1 and GIP receptors, potentially explaining its superior results. This news has implications for investors and patients, as Mounjaro's manufacturer, Eli Lilly, could see increased market share and revenue, while Novo Nordisk, the maker of Ozempic, might face competitive pressure. The article also touches on the broader market dynamics, including the potential for Mounjaro to become a preferred choice for weight management, affecting stock prices and future pharmaceutical developments in the obesity treatment sector.

Read the Full The Motley Fool Article at:
[ https://www.fool.com/investing/2024/12/18/ozempic-dethroned-a-head-to-head-study-confirms-th/ ]